生物素-七聚乙二醇-胺 | 1334172-76-7

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 中文名称: 生物素-七聚乙二醇-胺
• 英文名称: N-(23-amino-3,6,9,12,15,18,21-heptaoxatricosyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
• 英文别名: biotin-PEG7 amine；Biotin-PEG7-Amine；5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]pentanamide
• CAS: 1334172-76-7
• 化学式: C₂₆H₅₀N₄O₉S
• 分子量: 594.77
• InChiKey: HRGIYGOBSBFLMX-LSQMVHIFSA-N

物化性质

• 沸点：
  785.9±60.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)
• 溶解度：
  溶于水、DMSO、DCM、DMF

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  40
• 可旋转键数：
  28
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  186
• 氢给体数：
  4
• 氢受体数：
  11

安全信息

• WGK Germany：
  3

制备方法与用途

生物素-八聚乙二醇-氨基可用作医药合成中间体。如不慎吸入，请将患者移至空气新鲜处；若皮肤接触，应脱去污染衣物，并用肥皂水和清水彻底清洗皮肤，如有不适请就医；眼睛接触时，需分开眼睑，用流动清水或生理盐水冲洗，并立即就医；如果吞食，请立即漱口，禁止催吐，并立即寻求医疗帮助。

反应信息

• 作为反应物：
  描述：

  6-氯己酸 、 生物素-七聚乙二醇-胺 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  High-Throughput Chemical Probing of Full-Length Protein–Protein Interactions

  摘要：

  Human biology is regulated by a complex network of protein protein interactions (PPIs), and disruption of this network has been implicated in many diseases. However, the targeting of PPIs remains a challenging area for chemical probe and drug discovery. Although many methodologies have been put forth to facilitate these efforts, new technologies are still needed. Current biochemical assays for PPIs are typically limited to motif domain and domain domain interactions, and assays that will enable the screening of full-length protein systems, which are more biologically relevant, are sparse. To overcome this barrier, we have developed a new assay technology, "PPI catalytic enzyme-linked click chemistry assay" or PPI cat-ELCCA, which utilizes click chemistry to afford catalytic signal amplification. To validate this approach, we have applied PPI cat-ELCCA to the eIF4E-4E-BP1 and eIF4E-eIF4G PPIs, key regulators of cap-dependent mRNA translation. Using these examples, we have demonstrated that PPI cat-ELCCA is amenable to full-length proteins, large (>200 kDa) and small (similar to 12 kDa), and is readily adaptable to automated high-throughput screening. Thus, PPI cat-ELCCA represents a powerful new tool in the toolbox of assays available to scientists interested in the targeting of disease-relevant PPIs.

  DOI：

  10.1021/acscombsci.7b00128
• 作为产物：
  描述：

  (+)生物素-N-琥珀酰亚胺基酯 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 生物素-七聚乙二醇-胺
  参考文献：
  名称：

  High-Throughput Chemical Probing of Full-Length Protein–Protein Interactions

  摘要：

  Human biology is regulated by a complex network of protein protein interactions (PPIs), and disruption of this network has been implicated in many diseases. However, the targeting of PPIs remains a challenging area for chemical probe and drug discovery. Although many methodologies have been put forth to facilitate these efforts, new technologies are still needed. Current biochemical assays for PPIs are typically limited to motif domain and domain domain interactions, and assays that will enable the screening of full-length protein systems, which are more biologically relevant, are sparse. To overcome this barrier, we have developed a new assay technology, "PPI catalytic enzyme-linked click chemistry assay" or PPI cat-ELCCA, which utilizes click chemistry to afford catalytic signal amplification. To validate this approach, we have applied PPI cat-ELCCA to the eIF4E-4E-BP1 and eIF4E-eIF4G PPIs, key regulators of cap-dependent mRNA translation. Using these examples, we have demonstrated that PPI cat-ELCCA is amenable to full-length proteins, large (>200 kDa) and small (similar to 12 kDa), and is readily adaptable to automated high-throughput screening. Thus, PPI cat-ELCCA represents a powerful new tool in the toolbox of assays available to scientists interested in the targeting of disease-relevant PPIs.

  DOI：

  10.1021/acscombsci.7b00128

文献信息

• [EN] NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES<br/>[FR] MOLÉCULES HÉTÉROBIVALENTES NON PEPTIDIQUES PERMETTANT LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018134731A1

  公开（公告）日：2018-07-26

  The present invention relates to non peptidic, heterobivalent molecules (HBM) that are able to simultaneously bind a surface target protein as well as an endogenous or exogenous human antibody protein and induce immune effector function. More specifically, the present invention relates to agents capable of binding to a chemokine receptor and inducing the depletion of chemokine receptor positive subsets of pathogenic cells in a subject for use in the treatment and/or prevention of cancer, inflammatory, autoimmune and allergic disease.

  本发明涉及能够同时结合表面靶蛋白和内源或外源人类抗体蛋白并诱导免疫效应功能的非肽类、异二价分子（HBM）。更具体地，本发明涉及能够结合趋化因子受体并诱导受体阳性病原细胞亚群在受试者中的减少的药剂，用于治疗和/或预防癌症、炎症、自身免疫和过敏性疾病。
• [EN] METHOD OF CONJUGATING A POLYPEPTIDE<br/>[FR] MÉTHODE DE CONJUGAISON D'UN POLYPEPTIDE
  申请人：MEDIMMUNE LLC

  公开号：WO2016054315A1

  公开（公告）日：2016-04-07

  The present disclosure relates to a method of conjugating a compound of formula (I) O 5 R1-Q— (ZL-COn-X-N O (I) with a polypeptide comprising at least one thiol group and molecules obtained from said method.

  本公开涉及一种将化合物（I）O 5 R1-Q—（ZL-COn-X-NO（I）与至少含有一个硫醇基团的多肽共轭的方法，以及从该方法获得的分子。
• Development of fluorophore labeled or biotinylated anticancer small molecule NSC243928
  作者：Rahul Prakash、Dustin W. Goodlett、Sheelu Varghese、Justyna Andrys、Fahidat A. Gbadamosi、Ricardo H. Arriaza、Megha Patel、Purushottam B. Tiwari、Tomasz Borowski、Maksymilian Chruszcz、Linda S. Shimizu、Geeta Upadhyay

  DOI：10.1016/j.bmc.2023.117171

  日期：2023.2

  cancer cell death with an unclear mechanism. We have developed chemical tools to identify the molecular mechanisms of NSC243928-LY6K interaction. Herein, we report on the development and synthesis of biotinylated and fluorophore-tethered derivatives of NSC243928 guided by docking studies and molecular dynamics. Surface plasmon resonance assay indicates that these derivatives retained a direct binding with

  小分子 NSC243928 与 LY6K 结合，LY6K 是治疗三阴性乳腺癌的潜在靶点，并诱导癌细胞死亡，但机制尚不清楚。我们开发了化学工具来识别 NSC243928-LY6K 相互作用的分子机制。在此，我们报告了在对接研究和分子动力学指导下 NSC243928 生物素化和荧光团束缚衍生物的开发和合成。表面等离子共振测定表明这些衍生物保留了与 LY6K 蛋白的直接结合。共聚焦分析显示，硝基苯并恶二唑 (NBD) 荧光团标记的 NSC243928 保留在表达 LY6K 的癌细胞中。这些新型修饰化合物将用于未来的体外和体内研究，以了解 NSC243928 介导的癌细胞死亡的分子机制。这些研究将为开发新型靶向疗法以及了解这些疗法对难以治疗的癌症（如三阴性乳腺癌或其他高表达 LY6K 的癌症）的任何潜在副作用铺平道路。
• NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20190336489A1

  公开（公告）日：2019-11-07

  The present invention relates to non peptidic, heterobivalent molecules (HBM) that are able to simultaneously bind a surface target protein as well as an endogenous or exogenous human antibody protein and induce immune effector function. More specifically, the present invention relates to agents capable of binding to a chemokine receptor and inducing the depletion of chemokine receptor positive subsets of pathogenic cells in a subject for use in the treatment and/or prevention of cancer, inflammatory, autoimmune and allergic disease.
• NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20210379044A1

  公开（公告）日：2021-12-09

  The present invention relates to non peptidic, heterobivalent molecules (HBM) that are able to simultaneously bind a surface target protein as well as an endogenous or exogenous human antibody protein and induce immune effector function. More specifically, the present invention relates to agents capable of binding to a chemokine receptor and inducing the depletion of chemokine receptor positive subsets of pathogenic cells in a subject for use in the treatment and/or prevention of cancer, inflammatory, autoimmune and allergic disease.